Search Orphan Drug Designations and Approvals
-
Generic Name: | tenalisib |
---|---|
Date Designated: | 04/04/2018 |
Orphan Designation: | Treatment of Cutaneous T-Cell Lymphoma |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Rhizen Pharmaceuticals SA 40 Rue Fritz-Courvoisier La Chaux-de-Fonds, Neuchâtel Switzerland The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-